PTT 4256
Alternative Names: PTT-4256Latest Information Update: 28 Nov 2024
At a glance
- Originator Pathios Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action GPR65 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 04 Nov 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (PO) (NCT06634849)
- 18 Apr 2024 Pathios Therapeutics plans clinical trial in Solid tumor (PO) by the end of 2024
- 19 Apr 2023 Preclinical trials in Solid tumours in United Kingdom (PO) before April 2023